Hyphens Pharma International

Contracts

Hyphens Pharma signs exclusive licensing deal of Ustekinumab biosimilar for Singapore, Malaysia and the Philippines

The exclusive license and supply agreement will not have a material effect on the group’s NTA or EPS for FY2021.
Hyphens Pharma 9M21 PATMI exceeds expectations amidst speed bump in Vietnam: PhillipCapital  - THE EDGE SINGAPORE

Broker's Calls

Hyphens Pharma 9M21 PATMI exceeds expectations amidst speed bump in Vietnam: PhillipCapital

For the 9MFY2021 ended September, Hyphens Pharma reported PATMI of $1.09 million, 28.8% higher y-o-y
Hyphens Pharma acquires Novem group of companies for $16.3 mil - THE EDGE SINGAPORE

M&A

Hyphens Pharma acquires Novem group of companies for $16.3 mil

The acquisition will be earnings accretive for Hyphens Pharma.

Medtech

Hyphens Pharma awarded e-pharmacy licence for WellAway Pharmacy

Shares in Hyphens Pharma closed 1 cent higher or 3.2% up at 32.5 cents on Jan 7.
960 Brokers' Digest - THE EDGE SINGAPORE

Broker's Calls

960 Brokers' Digest

Take a look at these six stocks this week, including Silverlake, Genting Singapore and Hyphens Pharma.
959 Brokers' Digest - THE EDGE SINGAPORE

Broker's Calls

959 Brokers' Digest

Take a look at these six stocks this week, including Starburst Holdings, Netllink NBN Trust and StarHub.
KGI gives Hyphens a ‘buy', saying 'skin is the game' - THE EDGE SINGAPORE

Broker's Calls

KGI gives Hyphens a ‘buy', saying 'skin is the game'

KGI is initiating coverage on Hyphens Pharma with an “outperform” call and a target price of 48 cents.

Healthcare

Hyphens Pharma enjoys lift from broader product range and wider distribution channels

Hyphens’ CFO Fang Lee Wei sayS the counter was “under-recognised and severely undervalued” in its first 18 months since listing.

Broker's Calls

PhillipCapital remains positive on Hyphens Pharma following 'intact' underlying 1H20 revenue growth

On August 13, Hyphens Pharma posted a 32% y-o-y surge in earnings of $2.2 million for 2Q20 ended June, and $4.3 million for the 1H20, which represented a 39.8% growth.
×